Evogene Ltd.

NASDAQ: EVGN · Real-Time Price · USD
1.33
-0.03 (-2.21%)
At close: Aug 15, 2025, 1:26 PM

Evogene Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-18.05M -25.95M -29.84M -30.45M
Depreciation & Amortization
2.5M 2.61M 2.58M 2.23M
Stock-Based Compensation
1.79M 1.88M 1.19M 2.61M
Other Working Capital
-1.17M -178K 239K 1.18M
Other Non-Cash Items
-2.64M 321K 3.08M -906K
Deferred Income Tax
9K -33K 90K 13K
Change in Working Capital
-3.31M -400K -771K 1.66M
Operating Cash Flow
-19.7M -21.58M -23.68M -24.84M
Capital Expenditures
-626K -785K -1.17M -724K
Cash Acquisitions
n/a n/a n/a n/a
Purchase of Investments
-17.15M -10.7M -911K -24.11M
Sales Maturities Of Investments
27.34M 6.92M 15.36M 4.39M
Other Investing Acitivies
58K 26K n/a n/a
Investing Cash Flow
9.62M -4.54M 13.27M -20.44M
Debt Repayment
-901K -836K 9.2M -580K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
n/a n/a n/a n/a
Other Financial Acitivies
5.43M 10.54M 125K 1.27M
Financial Cash Flow
4.66M 18.15M 9.34M 30.28M
Net Cash Flow
-5.47M -8.21M -3.35M -13.9M
Free Cash Flow
-20.33M -22.36M -24.85M -25.56M